About MeiraGTx

MeiraGTx develops gene therapies that address both inherited retinal diseases and widespread conditions like Parkinson's disease and metabolic disorders. The company combines cutting edge viral vector design with proprietary riboswitch technology, enabling precise, controllable gene expression through oral medication. This flexibility expands genetic medicine beyond traditional applications. MeiraGTx operates end to end in house GMP manufacturing across facilities in the US, UK, and Ireland, ensuring quality control from vector design through clinical production. Each therapy targets specific patient needs, from restoring sight in children with congenital blindness to managing chronic neurological and metabolic conditions in adults.